Imaging 2-hydroxyglutarate and other brain oncometabolites pertinent to critical genomic alterations in brain tumors

The 2021 World Health Organization (WHO) Classification of Tumors of the Central Nervous System (CNS) and recent smaller annual updates have shown that alterations in tumor genetics are essential to determining tumor diagnosis, biological activity, and potential treatment options. This review summar...

Descripción completa

Detalles Bibliográficos
Autores principales: Thomas, Teena, Thakur, Sunitha, Young, Robert
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The British Institute of Radiology. 2023
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10077413/
https://www.ncbi.nlm.nih.gov/pubmed/37035765
http://dx.doi.org/10.1259/bjro.20210070
_version_ 1785020296181317632
author Thomas, Teena
Thakur, Sunitha
Young, Robert
author_facet Thomas, Teena
Thakur, Sunitha
Young, Robert
author_sort Thomas, Teena
collection PubMed
description The 2021 World Health Organization (WHO) Classification of Tumors of the Central Nervous System (CNS) and recent smaller annual updates have shown that alterations in tumor genetics are essential to determining tumor diagnosis, biological activity, and potential treatment options. This review summarizes the most important mutations and oncometabolites, with a focus on the central role played by 2-hydroxyglutarate in isocitrate dehydrogenase mutant tumors, as well as their corresponding imaging counterparts using standard and advanced imaging techniques.
format Online
Article
Text
id pubmed-10077413
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher The British Institute of Radiology.
record_format MEDLINE/PubMed
spelling pubmed-100774132023-04-07 Imaging 2-hydroxyglutarate and other brain oncometabolites pertinent to critical genomic alterations in brain tumors Thomas, Teena Thakur, Sunitha Young, Robert BJR Open Review Article The 2021 World Health Organization (WHO) Classification of Tumors of the Central Nervous System (CNS) and recent smaller annual updates have shown that alterations in tumor genetics are essential to determining tumor diagnosis, biological activity, and potential treatment options. This review summarizes the most important mutations and oncometabolites, with a focus on the central role played by 2-hydroxyglutarate in isocitrate dehydrogenase mutant tumors, as well as their corresponding imaging counterparts using standard and advanced imaging techniques. The British Institute of Radiology. 2023-03-22 /pmc/articles/PMC10077413/ /pubmed/37035765 http://dx.doi.org/10.1259/bjro.20210070 Text en © 2023 The Authors. Published by the British Institute of Radiology https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution and reproduction in any medium, provided the original author and source are credited.
spellingShingle Review Article
Thomas, Teena
Thakur, Sunitha
Young, Robert
Imaging 2-hydroxyglutarate and other brain oncometabolites pertinent to critical genomic alterations in brain tumors
title Imaging 2-hydroxyglutarate and other brain oncometabolites pertinent to critical genomic alterations in brain tumors
title_full Imaging 2-hydroxyglutarate and other brain oncometabolites pertinent to critical genomic alterations in brain tumors
title_fullStr Imaging 2-hydroxyglutarate and other brain oncometabolites pertinent to critical genomic alterations in brain tumors
title_full_unstemmed Imaging 2-hydroxyglutarate and other brain oncometabolites pertinent to critical genomic alterations in brain tumors
title_short Imaging 2-hydroxyglutarate and other brain oncometabolites pertinent to critical genomic alterations in brain tumors
title_sort imaging 2-hydroxyglutarate and other brain oncometabolites pertinent to critical genomic alterations in brain tumors
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10077413/
https://www.ncbi.nlm.nih.gov/pubmed/37035765
http://dx.doi.org/10.1259/bjro.20210070
work_keys_str_mv AT thomasteena imaging2hydroxyglutarateandotherbrainoncometabolitespertinenttocriticalgenomicalterationsinbraintumors
AT thakursunitha imaging2hydroxyglutarateandotherbrainoncometabolitespertinenttocriticalgenomicalterationsinbraintumors
AT youngrobert imaging2hydroxyglutarateandotherbrainoncometabolitespertinenttocriticalgenomicalterationsinbraintumors

Ejemplares similares